RVPHW
Get informed when a big investor buys or sells
+ Follow| P/E Ratio | Dividends | Return on Equity | Price-to-Sales | Debt-to-Equity | ||
|---|---|---|---|---|---|---|
| 0 | - | -113901094% | - | - | ||
Undervalued by 12990% based on the discounted cash flow analysis.
| Market cap | $5.74 Million |
|---|---|
| Enterprise Value | $-16,218,578.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.48 |
| Beta | -0.03 |
| Outstanding Shares | 7,022,945 |
| P/E Ratio | -0.05 |
|---|---|
| PEG | 0.09 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0.01 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Reviva Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Reviva's primary ...